ANK-302 / Ankyra Therap - LARVOL DELTA

Ankyra Therapeutics to Present Data at SITC 2026 Supporting Anchored Immunotherapy with Multiple Cancer-Fighting Agonists for Localized Tumor Treatment (Businesswire) - "The three accepted abstracts focus on preclinical data demonstrating how Ankyra’s anchored immunotherapy platform can be applied to multiple immune-modulating agonists, including CD40, CD28, CD137 (4-1BB), and IL-2/IL-15, to precisely target localized solid tumors and anchor powerful cancer-fighting therapeutics in the tumor microenvironment to minimize side effects and maximize therapeutic effect."

Preclinical • Solid Tumor

Safety and efficacy of ANK-302, an alum anchored CD28 and IL-2 bi-agonist in preclinical tumor models (SITC 2026) - No abstract available

Preclinical • Oncology • IL2